Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

We report a patient with congenital myasthenic syndrome (CMS) due to mutation in CHRNE with symptoms since the age of 4; mild to moderate fatigable weakness involved mainly ocular, bulbar and limb muscles; functional impact of the disease in their development and physical activity was modest. By the age of 34, the patient experienced gradual worsening of fatigue with dyspnoea and pronounced limb weakness, requiring significant increase of pyridostigmine. Further, a remarkable and sustained clinical improvement followed thymectomy with hyperplastic thymus. Despite of the absence of detectable antibodies to acetyl-choline receptor (AChR) (including clustered-AChR), muscle-specific kinase and low-density lipoprotein receptor-related protein-4 antibodies in the serum obtained nine years after thymectomy, the clinical, genetic and histological features are in keeping with the extremely rare association of two rare neuromuscular junction disorders - CMS and myasthenia gravis (MG). The inexistence of other conditions that could potentially associate with thymic hyperplasia also supports the diagnosis of MG.

Original publication

DOI

10.1016/j.nmd.2015.08.001

Type

Journal article

Journal

Neuromuscul Disord

Publication Date

12/2015

Volume

25

Pages

928 - 931

Keywords

Congenital myasthenic syndrome, Myasthenia gravis, Neuromuscular junction disorder, Adult, Disease Progression, Humans, Male, Muscle, Skeletal, Mutation, Myasthenia Gravis, Myasthenic Syndromes, Congenital, Receptors, Nicotinic, Thymectomy, Thymus Hyperplasia